![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Coherus’ Neulasta Biosimilar Succeeds in Phase 3 Study
Coherus’ Neulasta Biosimilar Succeeds in Phase 3 Study
July 18, 2016
Coherus BioSciences has released positive results from a pharmacokinetic and pharmacodynamic study assessing its biosimilar candidate CHS-1701.
In the biosimilarity study comparing CHS-1701 to Amgen’s Neulasta, the candidate reached all of its co-primary endpoints.
Overall, there were no adverse events related to the treatment.
Upcoming Events
-
21Oct